JP2022516989A5 - - Google Patents

Info

Publication number
JP2022516989A5
JP2022516989A5 JP2021539972A JP2021539972A JP2022516989A5 JP 2022516989 A5 JP2022516989 A5 JP 2022516989A5 JP 2021539972 A JP2021539972 A JP 2021539972A JP 2021539972 A JP2021539972 A JP 2021539972A JP 2022516989 A5 JP2022516989 A5 JP 2022516989A5
Authority
JP
Japan
Prior art keywords
weight
pharmaceutical composition
composition according
amount
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021539972A
Other languages
English (en)
Japanese (ja)
Other versions
JP7489989B2 (ja
JP2022516989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012649 external-priority patent/WO2020146441A1/en
Publication of JP2022516989A publication Critical patent/JP2022516989A/ja
Publication of JP2022516989A5 publication Critical patent/JP2022516989A5/ja
Application granted granted Critical
Publication of JP7489989B2 publication Critical patent/JP7489989B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539972A 2019-01-09 2020-01-08 (s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む医薬組成物及びその使用方法 Active JP7489989B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962790229P 2019-01-09 2019-01-09
US62/790,229 2019-01-09
PCT/US2020/012649 WO2020146441A1 (en) 2019-01-09 2020-01-08 Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same

Publications (3)

Publication Number Publication Date
JP2022516989A JP2022516989A (ja) 2022-03-03
JP2022516989A5 true JP2022516989A5 (cg-RX-API-DMAC7.html) 2023-01-24
JP7489989B2 JP7489989B2 (ja) 2024-05-24

Family

ID=69500831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539972A Active JP7489989B2 (ja) 2019-01-09 2020-01-08 (s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む医薬組成物及びその使用方法

Country Status (12)

Country Link
US (3) US11779580B2 (cg-RX-API-DMAC7.html)
EP (1) EP3908254A1 (cg-RX-API-DMAC7.html)
JP (1) JP7489989B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210113290A (cg-RX-API-DMAC7.html)
CN (2) CN114409630B (cg-RX-API-DMAC7.html)
AU (1) AU2020206692B2 (cg-RX-API-DMAC7.html)
CA (1) CA3126067A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191904A1 (cg-RX-API-DMAC7.html)
IL (1) IL284665B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021008321A (cg-RX-API-DMAC7.html)
SG (1) SG11202107438WA (cg-RX-API-DMAC7.html)
WO (1) WO2020146441A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2988714T3 (es) 2020-07-07 2024-11-21 Celgene Corp Composiciones farmacéuticas que comprenden (S)-4-(4-(4-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencilo)piperazin-1-il)-3-fluorobenzonitrilo y métodos de uso de las mismas
KR20240013793A (ko) 2021-05-27 2024-01-30 셀진 코포레이션 조합 요법을 사용하는 다발성 골수종의 치료 방법
WO2025240252A1 (en) * 2024-05-13 2025-11-20 Beta Pharma, Inc. Estrogen receptor degraders as treatments for breast cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
PY0323128A (es) * 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
SG183257A1 (en) * 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2604248B1 (en) * 2011-12-13 2017-10-25 Unilever PLC Oil-in-water cosmetic composition
WO2014191806A2 (en) * 2013-05-02 2014-12-04 Effrx Pharmaceuticals Sa Effervescent formulations that deliver particles which float in the stomach
UA117141C2 (uk) * 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
IL278854B2 (en) 2018-05-23 2026-01-01 Celgene Corp Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
PL3796912T3 (pl) * 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
EP3908582B1 (en) * 2019-01-09 2025-11-12 Celgene Corporation Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
DK3908281T3 (da) 2019-01-09 2024-10-21 Celgene Corp Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom

Similar Documents

Publication Publication Date Title
JP2022537772A (ja) 新規egfr阻害剤
JP2021063088A5 (cg-RX-API-DMAC7.html)
AU2019391097B2 (en) CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
EP3630726B1 (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
JP2022543155A5 (cg-RX-API-DMAC7.html)
JP2017537158A5 (cg-RX-API-DMAC7.html)
RU2015151938A (ru) Таблетируемый препарат (4'-трифторметилфенил)амида (z)-2-циано-3-гидрокси-бут-2-еноевой кислоты с улучшенной устойчивостью
EA036098B1 (ru) Способ получения противогрибковых соединений
CN106458900A (zh) 抗真菌化合物的制备方法
JP2022553954A5 (cg-RX-API-DMAC7.html)
JP6814886B2 (ja) ベンゾイミダゾール誘導体を含む新規な製剤
JPH03151374A (ja) 新規化合物、その製法及びそれを含む医薬組成物
US11130740B2 (en) Substituted 2,3-dihydro-1H-indene analogs and methods using same
JP2022541938A5 (cg-RX-API-DMAC7.html)
CN115916750A (zh) 用于制备具有经取代的苯基或吡啶基部分的serd三环化合物的方法
WO2002020539A1 (en) Adenosine derivatives and use thereof
HUP0001878A2 (hu) (R)-3-(N,N-diciklobutil-amino)-8-fluor-3,4-dihidro-2H-1-benzopirán-5-karboxamid-hidrogén tartarát, eljárás előállítására és ezt tartalmazó gyógyszerkészítmények
CA3099786A1 (en) Crystalline form of s-apomorphine
KR100830002B1 (ko) 시부트라민의 무기산염
JP2016539994A (ja) α,ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
JP2003055217A (ja) 医薬組成物
US20240010641A1 (en) N-Linked Glycosylation Inhibitors and Methods of Using Same
JP2025532537A (ja) Cd73阻害剤の医薬形態
JP2023533314A5 (cg-RX-API-DMAC7.html)
CN1353711A (zh) 结晶性氮杂双环[2,2,2]辛烷-3-胺柠檬酸盐的多晶型物及其药物组合物